A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer

PURPOSE: Notch signaling dysregulation is implicated in the development of pancreatic adenocarcinoma (PDAC). Tarextumab is a fully human IgG2 antibody that inhibits Notch2/3 receptors. PATIENTS AND METHODS: Aphase 2, randomized, placebo‐controlled, multicenter trial evaluated the activity of tarextu...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Cancer Med
मुख्य लेखकों: Hu, Zishuo Ian, Bendell, Johanna C., Bullock, Andrea, LoConte, Noelle K., Hatoum, Hassan, Ritch, Paul, Hool, Hugo, Leach, Joseph W., Sanchez, James, Sohal, Davendra P. S., Strickler, John, Patel, Ravindranath, Wang‐Gillam, Andrea, Firdaus, Irfan, Yu, Kenneth H., Kapoun, Ann M., Holmgren, Eric, Zhou, Lei, Dupont, Jakob, Picozzi, Vincent, Sahai, Vaibhav, O'Reilly, Eileen M.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: John Wiley and Sons Inc. 2019
विषय:
Clinical Cancer Research
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6718621/
https://ncbi.nlm.nih.gov/pubmed/31347292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2425
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन